A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon

Translated title of the contribution: Experiences with price competition of biosimilar drugs in Hungary

Lajos Hornyák, Zsolt Nagy, Zsuzsanna Tálos, Dóra Endrei, István Ágoston, Tímea Csákvári, Imre Boncz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: The aim of our study is to analyse the biosimilar bids of the Hungarian National Health Insurance Fund Administration in case of colony-stimulating factor and erythropoietin products. Data and methods: Data derived from the nationwide pharmaceutical database of Hungarian National Health Insurance Fund Administration. We analysed how the number of patients treated by colony-stimulating factor and erythropoietin products changed before (01.07.2011.-30.06.2012.) and after (01.07.2012.-30.06.2013.) the first biosimilar bid performed in March 2012 in Hungary. Results: In the 12 months before biosimilar bid 4167 patients received erythropoietin treatment, while in the first 12 months after the bid 3647 patients, resulting in a 12.5% decline. In the 12 months before biosimilar bid 13974 patients received colony-stimulating factor treatment, while in the first 12 months after the bid 13352 patients, resulting in a 4.5% decline. Conclusions: The analyses of the Hungarian price competition bid of biosimilar products showed a minimal decline in the number of patients under treatment by both colony-stimulating factor and erythropoietin products while the health insurance reimbursement of these drugs significantly decreased.

Original languageHungarian
Pages (from-to)83-87
Number of pages5
JournalActa pharmaceutica Hungarica
Volume84
Issue number2
Publication statusPublished - 2014

    Fingerprint

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Hornyák, L., Nagy, Z., Tálos, Z., Endrei, D., Ágoston, I., Csákvári, T., & Boncz, I. (2014). A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon. Acta pharmaceutica Hungarica, 84(2), 83-87.